Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / TNFSF10



This biomarker is also known as:
  • Apo-2 ligand,
  • tumor necrosis factor (ligand) superfamily, member 10,
  • TNF-related apoptosis inducing ligand TRAIL,
  • TL2,
  • TNF-related apoptosis-inducing ligand,
  • APO2L,
  • CD253 antigen,
  • Protein TRAIL,
  • Apo-2L,
  • CD253,
  • chemokine tumor necrosis factor ligand superfamily member 10,
  • tumor necrosis factor (ligand) family, member 10,
  • tumor necrosis factor ligand superfamily member 10,
  • TRAIL,
  • tumor necrosis factor apoptosis-inducing ligand splice variant delta,

View in BioMuta


tumor necrosis factor (ligand) superfamily, member 10


QA State: Curated
Type: Gene
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


No additional prostate data available.

Performance Comment

19 common probe sets (15 unique genes) were used to develop a PAM-based classifier, which had an average accuracy of 87% when it was tested on 47 independent tumor-adjacent stroma samples. The 15 genes represented in the classifier are: GADD45B, CDKN1A, NLRP1, ERBB3, FMO5, KIAA0746///SERINC2, AMFR, DPP4, PGC, YWHAE, EHF, TF, TNFSF10, EIF5A, TGM4. This is the first general tumor microenvironment-based prognostic classifier. Tumor-adjacent prostate cancer stroma contains numerous changes in gene expression at the time of diagnosis that correlate with the chance of relapse following prostatectomy. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for predicting outcomes for patients.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take on a date and location to be determined.